Subscribe
istock-509483224-pills-2
19 April 2018Europe

Sanofi in talks to sell generics unit for €1.9bn

France-based Sanofi has confirmed it is in negotiations to sell its European generics business Zentiva for €1.9 billion ($2.4 billion) to private equity firm Advent International.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.

More on this story

Big Pharma
Sanofi to acquire Ablynx for €3.9bn
29 January 2018   Biopharmaceutical company Sanofi has revealed plans to acquire biotech firm Ablynx for approximately €3.9 billion ($4.8 billion).
Americas
Sanofi to buy Bioverativ for $11.6bn
23 January 2018   Paris-based Sanofi has revealed plans to acquire Bioverativ, a US-based biotech company focused on haemophilia treatments.
Europe
Advent agrees to buy Sanofi’s European generics unit
29 June 2018   Private equity investor Advent International has agreed to acquire France-based Sanofi's European generics business Zentiva.

More features

Fed Circ orders Teva to delist five patents from Orange Book
Sarepta wins $115M in patent dispute over muscular dystrophy drug
Novartis shields eye-drop patent at European Patent Office
CREATES Act unfairly tips the scales to generics
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York